Ask AI
ProCE Banner Activity

Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow mBC: Experts Answer Your Questions

Clinical Thought

This commentary provides insights from breast oncology experts answering questions from an audience of healthcare professionals posed during a live satellite symposium at the American Society of Clinical Oncology annual meeting, which explores the role of anti-HER2 antibody–drug conjugates in patients with HER2-low and HER2-ultralow metastatic breast cancer.

Released: July 02, 2025

Expiration: January 01, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Nadia Harbeck, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Viatris.

Ian Krop, MD, PhD: consultant/advisor/speaker: ALX Oncology, AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech/Roche, Novartis, Ottimo, Pfizer, Seagen.

Sarah L. Sammons, MD: researcher: Daiichi Sankyo, Relay Therapeutics, Seagen, Sermonix; consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Incyclix, Lilly, Novartis, Pfizer, Seagen, Sermonix.